Search
for
Sort by
Research 271–300 of 582
- Systemic Absorption and Pharmacokinetics of Five Novel Topical Dermatologic Agents: A Review
- Ritlecitinib: Efficacy of a Novel Therapy for Severe Alopecia Areata in Patients Aged 12 Years and Older
- A 52-Week Real-Life Study of Baricitinib in Moderate to Severe Alopecia Areata: Clinical, Trichoscopic Assessment and Patient Reported Outcomes
- Optimization of photobiomodulation therapy for spinal cord injury: A review
- Predictive Factors of Response and Real‐World Experience of Baricitinib on Alopecia Areata: A Single Tertiary Center Study on a 72 Patients' Cohort
- Defining a Therapeutic Window of Opportunity in Alopecia Areata: Predictors of Early Response to Baricitinib
- “<i>Nomen Omen</i>: The Myth of God Janus”
- Review of Promising Off-Label Use of Deucravacitinib
- The Extract of Periplaneta americana (L.) Promotes Hair Regrowth in Mice with Alopecia by Regulating the FOXO/PI3K/AKT Signaling Pathway and Skin Microbiota
- Comprehensive Safety Exposure‐Response Analysis to Support Ritlecitinib Dose Selection
- The Use of Janus Kinase Inhibitors for Primary Neutrophilic Cicatricial Alopecias
- Wiederbehaarung bei einem Patienten mit Alopecia universalis und Psoriasis vulgaris unter Deucravacitinib‐Therapie
- Hair follicle targeting via gelatin coated transferosomes loaded with tofacitinib citrate for enhanced treatment of alopecia areata: Clinical evaluation of alopecia areata patients
- Hair regrowth in a patient with alopecia universalis and psoriasis vulgaris during deucravacitinib therapy
- Efficacy and Tolerability of Brevilin-A, a Natural JAK Inhibitor, in Pediatric Alopecia Areata: A Case Series
- Mesenchymal Stem Cell Therapy in Alopecia Areata: Visual and Molecular Evidence from a Mouse Model
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- USE OF RITLECITINIB FOR THE TREATMENT OF ALOPECIA AREATA
- Distribution of SALT scores by Therapeutic Tesponse in Patients with Severe Alopecia After 52 weeks of Baricitinib Therapy
- Baricitinib: Exploring the Safety Profile for the Treatment of Alopecia Areata
- JAK inhibitor deuruxolitinib shows encouraging hair re-growth in alopecia areata
- Therapeutic potential of stem cell-derived exosomes in hair regeneration: A systematic review
- Mesenchymal Stem Cells for Regenerative Medicine
- The JAK/STAT signaling pathway: from bench to clinic
- Biological Function of Long Non-coding RNA (LncRNA) Xist
- Challenges, Progress, and Prospects of Developing Therapies to Treat Autoimmune Diseases
- Chemistry42: An AI-Driven Platform for Molecular Design and Optimization
- The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside
- Skin Pigmentation Types, Causes and Treatment—A Review
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results